New study points to a double-digit hike in branded drug prices, spotlighting a growing national debate
Over the last few months we’ve seen a string of big and small biopharma companies make public pledges to keep their annual drug price hikes limited to modest annual increases. But looking back over 2016, one gauge of drug price inflation highlights that the trends all point to only a modest “softening” of the hard price spikes the US has been seeing for years now.
Based on their analysis of billions of prescriptions written last year, Truveris says that the drug inflation rate hit 8.77% last year. Singling out branded drugs, the increase was a painful 13%. Generic drugs continued to hold the line, with only a fractional increase overall.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.